Edwards Lifesciences (EW) Tax Provisions (2009 - 2026)

Edwards Lifesciences has reported Tax Provisions for 18 years, with the latest figure at $78.3 million in Q1 2026.

• For the quarter ending Q1 2026, Tax Provisions rose 11.38% year-over-year to $78.3 million; the trailing twelve-month figure through Mar 2026 stood at $224.9 million (up 27.71% YoY), and the FY2025 full-year result was $216.9 million, up 42.6% from the prior year.
• Tax Provisions for Q1 2026 stood at $78.3 million, up from $26.2 million in the prior quarter.
• The five-year high for Tax Provisions was $78.3 million in Q1 2026, with the low at $10.9 million in Q4 2022.
• Average Tax Provisions over 5 years is $47.6 million, with a median of $52.7 million recorded in 2023.
• Year-over-year, Tax Provisions sank 73.41% in 2022 and jumped 221.5% in 2025.
• Tracing EW's Tax Provisions over 5 years: stood at $10.9 million in 2022, then surged by 212.84% to $34.1 million in 2023, then jumped by 32.26% to $45.1 million in 2024, then plunged by 41.91% to $26.2 million in 2025, then jumped by 198.85% to $78.3 million in 2026.
• The last three Tax Provisions figures came in at $78.3 million (Q1 2026), $26.2 million (Q4 2025), and $56.1 million (Q3 2025), per Business Quant data.

Peer Comparison